Pediatric Drug Safety Signal Detection: A New Drug–Event Reference Set for Performance Testing of Data-Mining Methods and Systems
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Better evidence regarding drug safety in the pediatric population might be generated from existing data sources such as spontaneous reporting systems and electronic healthcare records. The Global Research in Paediatrics (GRiP)-Network of Excellence aims to develop pediatric-specific methods that can be applied to these data sources. A reference set of positive and negative drug-event associations is required. OBJECTIVE: The aim of this study was to develop a pediatric-specific reference set of positive and negative drug-event associations. METHODS: Considering user patterns and expert opinion, 16 drugs that are used in individuals aged 0-18 years were selected and evaluated against 16 events, regarded as important safety outcomes. A cross-table of unique drug-event pairs was created. Each pair was classified as potential positive or negative control based on information from the drug's Summary of Product Characteristics and Micromedex. If both information sources consistently listed the event as an adverse event, the combination was reviewed as potential positive control. If both did not, the combination was evaluated as potential negative control. Further evaluation was based on published literature. RESULTS: Selected drugs include ibuprofen, flucloxacillin, domperidone, methylphenidate, montelukast, quinine, and cyproterone/ethinylestradiol. Selected events include bullous eruption, aplastic anemia, ventricular arrhythmia, sudden death, acute kidney injury, psychosis, and seizure. Altogether, 256 unique combinations were reviewed, yielding 37 positive (17 with evidence from the pediatric population and 20 with evidence from adults only) and 90 negative control pairs, with the remainder being unclassifiable. CONCLUSION: We propose a drug-event reference set that can be used to compare different signal detection methods in the pediatric population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This analysis recapitulates general trends in the enriched occurrence of specific classes of ADEs suggested by prior relevant research efforts11,27.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Diagnostic Medicine
Zhou, X., Obuchowski, N. A., & McClish, D. K. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9780470906514 · Cited by 1,784 · cited 1×
“Given that the composition of the lists of drugs and adverse events to be tested may have an extensive impact on performance assessment [35], we tried to ensure that the criteria and data sources that were utilized to create the reference set were independent of the data on which they will…”
MethodAndrews, A. M., Gerhardt, G. A., Daws, L. C., Shoaib, M., Mason, B. J., Heyser, C. J., De Lecea, L., Balster, R. L., Walsh, S., Dahmen, M. M., et al. (2010) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-540-68706-1_4410 · Cited by 322
Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function
Carmichael, J., & Shankel, S. W. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90223-2 · Cited by 235 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI [55].”
Drug use in children: cohort study in three European countries
Sturkenboom, M. C. J. M., Verhamme, K. M. C., Nicolosi, A., Murray, M. L., Neubert, A., Caudri, D., Picelli, G., Sen, E. F., Giaquinto, C., Cantarutti, L., et al. (2008) · BMJ · doi:10.1136/bmj.a2245 · Cited by 234 · cited 1×
“Based on four criteria, four (primary) lists of drugs were created: we compiled drugs that are frequently prescribed in pediatrics (including off-label use), on an outpatient basis in high-income countries (as per papers and reports of use) [21, 22]; to allow for inpatient databases to be assessed, we included drugs t…”
MethodSelf-citationLindquist, M., St??hl, M., Bate, A., Edwards, I. R., & Meyboom, R. H. B. (2000) · Drug Safety · doi:10.2165/00002018-200023060-00004 · Cited by 230 · cited 1×
“Projects such as OMOP and EU-ADR have also created reference sets but none was targeted to pediatrics; in addition, the construct of these reference sets was different [19, 31–33].”
Unlicensed and Off-Label Drug Use in Children: Implications for Safety
Choonara, I., & Conroy, S. (2002) · Drug Safety · doi:10.2165/00002018-200225010-00001 · Cited by 224
Retinoic Acid and Affective Disorders: The Evidence for an Association
Bremner, J. D., Shearer, K. D., & McCaffery, P. J. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r05993 · Cited by 195 · cited 2×
“…[42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51,…”
The neurobiology of retinoic acid in affective disorders
Bremner, J. D., & McCaffery, P. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.001 · Cited by 177 · cited 2×
“…of 37 positive associations: quinine–aplastic anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49];…”
Ross, R. G. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1149 · Cited by 167 · cited 1×
“…anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50];…”
Pliszka, S. R. (2007) · Neuropsychology Review · doi:10.1007/s11065-006-9017-3 · Cited by 158 · cited 1×
“…anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50];…”
Defining a Reference Set to Support Methodological Research in Drug Safety
Ryan, P. B., Schuemie, M. J., Welebob, E. M., Duke, J. D., Valentine, S., & Hartzema, A. G. (2013) · Drug Safety · doi:10.1007/s40264-013-0097-8 · Cited by 158 · cited 2×
“In the current project, drugs and events were selected independently, unlike EU-ADR and OMOP [19, 20].”
MethodStar, K., Norén, G. N., Nordin, K., & Edwards, I. R. (2011) · Drug Safety · doi:10.2165/11587540-000000000-00000 · Cited by 122 · cited 1×
“Starting with common adverse events observed in pediatrics, as reported by Star et al. [26], we selected only events that were deemed serious (as per the WHO definition [27]) and specific (to avoid misclassification).”
BackgroundLawrenson, R. A., Seaman, H. E., m, A. S., Williams, T. J., & Farmer, R. D. T. (2000) · Drug Safety · doi:10.2165/00002018-200023040-00006 · Cited by 120 · cited 1×
“For example, doxycycline (WHO-ATC code J01AA02) would be selected instead of minocycline (WHO-ATC code J01AA08) because although they both belong to the same class—‘WHO-ATC, fourth level’ (tetracyclines)—doxycycline was first marketed in 1967 [24], and minocycline in 1972 [25].”
BackgroundState dependent dissociation of HERG channel inhibitors
Stork, D., Timin, E., Berjukow, S., Huber, C., Hohaus, A., Auer, M., & Hering, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707356 · Cited by 118 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI…”
Coloma, P. M., Avillach, P., Salvo, F., Schuemie, M. J., Ferrajolo, C., Pariente, A., Fourrier‐Réglat, A., Molokhia, M., Patadia, V. K., van der Lei, J., et al. (2012) · Drug Safety · doi:10.1007/s40264-012-0002-x · Cited by 100 · cited 7×
“In addition, controlled vocabulary was included for the concept ‘general adverse drug reaction’; this was done to increase the probability of retrieving only those articles where adverse event and drug co-occurred in the context of drug safety [19].”
BackgroundMethodResultInfluentialSelf-citationSchuemie, M. J., Coloma, P. M., Straatman, H., Herings, R. M. C., Trifirò, G., Matthews, J. N., Prieto‐Merino, D., Molokhia, M., Pedersen, L. H., Gini, R., et al. (2012) · Medical Care · doi:10.1097/mlr.0b013e31825f63bf · Cited by 95 · cited 1×
“…mining longitudinal data in EHRs, as described by the European Adverse Drug Reaction (EU-ADR) project—‘Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge’ and the ‘Observational Medical Outcomes Partnership’ (OMOP) project [15–17].”
MethodSelf-citationStanat, S. J. C., Carlton, C. G., Crumb, W., Agrawal, K. C., & Clarkson, C. W. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1027309703313 · Cited by 91 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI [55].”
White, N. J., Looareesuwan, S., & Warrell, D. A. (1983) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198303000-00001 · Cited by 91 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI [55].”
Alvarez, Y., Hidalgo, A. A. T., Maignen, F. M., & Slattery, J. (2010) · Drug Safety · doi:10.2165/11534410-000000000-00000 · Cited by 89 · cited 1×
“Those changes may have an impact on the ability to detect associations (for example, in spontaneous reporting databases it may increase the association, whereas it may decrease in electronic healthcare databases) [57–59].”
BackgroundElectronic healthcare databases for active drug safety surveillance: is there enough leverage?
Coloma, P. M., Trifirò, G., Schuemie, M. J., Gini, R., Herings, R. M. C., Hippisley‐Cox, J., Mazzaglia, G., Picelli, G., Corrao, G., Pedersen, L. H., et al. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3197 · Cited by 86
Self-citationMontelukast and psychiatric disorders in children
Wallerstedt, S. M., Brunlöf, G., Sundström, A., & Eriksson, A. L. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1794 · Cited by 86
Comparison of the Effects of Metoclopramide and Domperidone on HERG Channels
Claassen, S., & Zünkler, B. J. (2005) · Pharmacology · doi:10.1159/000083234 · Cited by 74 · cited 1×
“[43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; domperidone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI…”
A correlation between changes in GABA metabolism and isonicotinic acid hydrazide-induced seizures
Wood, J. D., & Peesker, S. J. (1972) · Brain Research · doi:10.1016/0006-8993(72)90477-5 · Cited by 65 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI [55].”
Unlicensed and Off-Label Drug Use: Issues and Recommendations
Conroy, S. (2002) · Pediatric Drugs · doi:10.2165/00128072-200204060-00002 · Cited by 63
Maguire, R. B., Stroncek, D. F., & Campbell, A. C. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-3-199308010-00006 · Cited by 63 · cited 1×
“However, we were able to find such evidence for only 13 of 37 positive associations: quinine–aplastic anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45];…”
BackgroundUnlicensed and off-label drug use in children: implications for safety
Choonara, I. (2004) · Expert Opinion on Drug Safety · doi:10.1517/eods.3.2.81.27342 · Cited by 59
Ibuprofen-induced hypersensitivity syndrome
Nanau, R. M., & Neuman, M. G. (2010) · Translational research · doi:10.1016/j.trsl.2010.01.005 · Cited by 56 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI [55].”
Bertuola, F., Morando, C., Menniti-Ippolito, F., Da Cas, R., Capuano, A., Perilongo, G., & Da Dalt, L. (2010) · Drug Safety · doi:10.2165/11530350-000000000-00000 · Cited by 53 · cited 1×
“…were supported by evidence generated exclusively from this age group: a case-control study for clarithromycin–thrombocytopenia [37]; case reports (more than three) for montelukast–psychosis [38]; review of spontaneous reports for montelukast–suicide [39]; and clinical trials…”
MethodUnlicensed and off-label drug use in children: implications for safety
Choonara, I. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.2.81 · Cited by 53 · cited 1×
“However, such evidence was not mandatory for classification as positive control due to the acknowledged lack of pediatric-specific studies [30].”
BackgroundValkhoff, V. E., Schade, R., Jong, G. W. ‘., Romio, S., Schuemie, M. J., Arfè, A., Garbe, E., Herings, R. M. C., Lucchi, S. R., Picelli, G., et al. (2013) · BMC Pediatrics · doi:10.1186/1471-2431-13-192 · Cited by 52 · cited 1×
“Therefore, other and preferably existing data sources should be utilized to provide information on the safety of drugs in pediatrics [12].”
BackgroundSelf-citationPotential for Electronic Health Records and Online Social Networking to Redefine Medical Research
Pearson, J. F., Brownstein, C. A., & Brownstein, J. S. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148668 · Cited by 50 · cited 1×
“Sets with drugs for inpatient use may favour performance of data mining on SRS databases, while sets utilizing drugs prescribed for outpatient treatments may favour mining performance on EHR databases [34].”
BackgroundAn Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database
Hochberg, A. M., Hauben, M., Pearson, R. K., O’Hara, D. J., Reisinger, S. J., Goldsmith, D. I., Gould, A. L., & Madigan, D. (2009) · Drug Safety · doi:10.2165/00002018-200932060-00007 · Cited by 47 · cited 1×
“Projects such as OMOP and EU-ADR have also created reference sets but none was targeted to pediatrics; in addition, the construct of these reference sets was different [19, 31–33].”
A time-indexed reference standard of adverse drug reactions
Harpaz, R., Odgers, D., Gaskin, G., DuMouchel, W., Winnenburg, R., Bodenreider, O., Ripple, A., Szarfman, A., Sorbello, A. F., Horvitz, E., et al. (2014) · Scientific Data · doi:10.1038/sdata.2014.43 · Cited by 47
Vlahović–Palčevski, V., & Mentzer, D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-20195-0_17 · Cited by 46
Effects of GABA and diazepam on 3H-serotonin release from hippocampal synaptosomes
Balfour, D. J. K. (1980) · European Journal of Pharmacology · doi:10.1016/0014-2999(80)90054-0 · Cited by 45
Hauben, M., Reich, L., & Chung, S. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0834-0 · Cited by 43 · cited 1×
“addition, the construct of these reference sets was different [19, 31–33].”
ResultAntiarrhythmic Activity of Quinine in Humans
Sheldon, R. S., Duff, H. J., & Koshman, M. L. (1995) · Circulation · doi:10.1161/01.cir.92.10.2944 · Cited by 42 · cited 1×
“…[44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50]; quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis [53]; isoniazid–seizure [54]; and ibuprofen–AKI [55].”
Bygdell, M., Brunlöf, G., Wallerstedt, S. M., & Kindblom, J. M. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2265 · Cited by 41 · cited 1×
“…exclusively from this age group: a case-control study for clarithromycin–thrombocytopenia [37]; case reports (more than three) for montelukast–psychosis [38]; review of spontaneous reports for montelukast–suicide [39]; and clinical trials as well as case series for methylphenidate–psychosis [40].”
BackgroundZoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance
Norén, G. N., Caster, O., Juhlin, K., & Lindquist, M. (2014) · Drug Safety · doi:10.1007/s40264-014-0198-z · Cited by 40 · cited 1×
“Those changes may have an impact on the ability to detect associations (for example, in spontaneous reporting databases it may increase the association, whereas it may decrease in electronic healthcare databases) [57–59].”
BackgroundPediatric Clinical Pharmacology
Seyberth, H. W., Schwab, M., & Rane, A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-20195-0 · Cited by 39
Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA
Peterson, J. A., Nelson, T. N., Kanack, A. J., & Aster, R. H. (2007) · Blood · doi:10.1182/blood-2007-09-112680 · Cited by 36 · cited 1×
“…to find such evidence for only 13 of 37 positive associations: quinine–aplastic anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48];…”
Brinker, A. D., & Beitz, J. G. (2002) · American Journal of Hematology · doi:10.1002/ajh.10148 · Cited by 36 · cited 1×
“This is possibly because quinine has been in use for a long time, both as over-the-counter (OTC) and prescription drug [56]; therefore, its safety profile has been well investigated.”
BackgroundPhan, H., Leder, M. S., Fishley, M., Moeller, M. L., & Nahata, M. (2010) · Pediatric Emergency Care · doi:10.1097/pec.0b013e3181e057e1 · Cited by 34 · cited 1×
“This is of particular concern as the impact of adverse events during growth and maturation may be more serious and longer term compared with adults [4–8].”
Pincus, T. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80002-2 · Cited by 31 · cited 1×
“Although useful for efficacy, such trials are usually too small and with too short a follow-up to yield adequate information on rare adverse drug reactions (ADR) and long-term safety [11].”
BackgroundEU-ADR consortium, Ferrajolo, C., Coloma, P. M., Verhamme, K. M. C., Schuemie, M. J., de Bie, S., Gini, R., Herings, R., Mazzaglia, G., Picelli, G., et al. (2014) · Drug Safety · doi:10.1007/s40264-013-0132-9 · Cited by 30 · cited 1×
“Longitudinal Gamma Poisson Shrinker (LGPS), show promising results in pediatric data [18], more extensive and systematic testing is needed.”
BackgroundSelf-citationThe Dawn of Pharmacovigilance: An Historical Perspective
van Grootheest, K. (2003) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200317050-00006 · Cited by 29
A plea for a more epidemiological and patient-oriented pharmacovigilance
Scurti, V., Romero, M., & Tognoni, G. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1096-2 · Cited by 28 · cited 2×
“In the last 50 years, drug safety monitoring has developed rapidly in terms of increasing interest, broadening capacity, innovation of methods and availability of data [1–3].”
BackgroundSutherland, R. L., Vincent, P. C., Raik, E., & Burgess, K. (1977) · BMJ · doi:10.1136/bmj.1.6061.605 · Cited by 27 · cited 1×
“However, we were able to find such evidence for only 13 of 37 positive associations: quinine–aplastic anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45];…”
BackgroundVaccine-Based Subgroup Analysis in VigiBase: Effect on Sensitivity in Paediatric Signal Detection
de Bie, S., Verhamme, K. M. C., Straus, S. M. J. M., Stricker, B. H. C., & Sturkenboom, M. (2012) · Drug Safety · doi:10.2165/11598120-000000000-00000 · Cited by 20 · cited 1×
“[14] proposed further refinement of these methods.”
Self-citationShibib, S., & Chalhoub, N. (2009) · Child and Adolescent Mental Health · doi:10.1111/j.1475-3588.2008.00490.x · Cited by 20 · cited 1×
“…exclusively from this age group: a case-control study for clarithromycin–thrombocytopenia [37]; case reports (more than three) for montelukast–psychosis [38]; review of spontaneous reports for montelukast–suicide [39]; and clinical trials as well as case series for methylphenidate–psychosis [40].”
BackgroundFramework conditions facilitating paediatric clinical research
Knellwolf, A., Bauzon, S., Alberighi, O. D. C., Lutsar, I., Bácsy, E., Alfarez, D. N., & Panei, P. (2011) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-37-12 · Cited by 19 · cited 1×
“This is of particular concern as the impact of adverse events during growth and maturation may be more serious and longer term compared with adults [4–8].”
Pharmacovigilance en pédiatrie
Autret‐Leca, E., Marchand, M.-S., Cissoko, H., Beau-Salinas, F., & Jonville‐Béra, A. ‐. (2012) · Archives de Pédiatrie · doi:10.1016/j.arcped.2012.05.013 · Cited by 12
Attempted suicide following treatment with isoniazid
Madan, A., Jain, N. K., Sharma, T. N., Sharma, D. K., & Madan, R. A. (1989) · Tubercle · doi:10.1016/0041-3879(89)90041-x · Cited by 11 · cited 1×
“However, a case report described the occurrence of suicide attempt following ingestion of isoniazid [36]; therefore, this association could not be confirmed as negative control.”
BackgroundReconciling the risk of QT interval prolongation in antidepressants
McKean, A. J. S., Sola, C. L., Galardy, C. W., Kung, S., & Lineberry, T. W. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3216 · Cited by 11
van Grootheest, K. (2003) · International Journal of Pharmaceutical Medicine · doi:10.1097/00124363-200317050-00006 · Cited by 10 · cited 1×
“In the last 50 years, drug safety monitoring has developed rapidly in terms of increasing interest, broadening capacity, innovation of methods and availability of data [1–3].”
BackgroundSchuemie, M. J., Coloma, P. M., Straatman, H., et al. (2012) · UCL Discovery (University College London) · Cited by 9
Pharmacovigilance in a changing world
Meyboom, R. H. B. (2011) · Klinická farmakologie a farmacie · Cited by 4
Reply to Drs. Nauta and van Domburg
Haukka, J. K., NISKANEN, L. K., Partonen, T., Lönnqvist, J. K., & Tiihonen, J. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3222 · Cited by 1
Cited by
Ziesenitz, V. C., Welzel, T., van Dyk, M., Saur, P., Gorenflo, M., & van den Anker, J. N. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00514-1 · Cited by 101
Fukazawa, C., Hinomura, Y., Kaneko, M., & Narukawa, M. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4672 · Cited by 57
Medication safety research by observational study design
Lao, K. S. J., Chui, C. S. L., Man, K. K. C., Lau, W. C. Y., Chan, E. W., & Wong, I. C. K. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-016-0285-6 · Cited by 43
“In recent years, there has been significant methodological development in using spontaneous reporting databases [31, 32] or prescribing data alone [33].”
BackgroundSelf-citationThe State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies
Zafarí, Z., Park, J.-E., Shah, C. H., dosReis, S., Gorman, E. F., Hua, W., Ma, Y., & Tian, F. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad201 · Cited by 28
Osokogu, O. U., Dodd, C. N., Pacurariu, A. C., Kaguelidou, F., Weibel, D. M., & Sturkenboom, M. (2016) · Drug Safety · doi:10.1007/s40264-016-0433-x · Cited by 19
Self-citation
Metadata
- Authors
- Osokogu, O. U., Fregonese, F., Ferrajolo, C., Verhamme, K., de Bie, S., Jong, G. ’., Catapano, M., Weibel, D., Kaguelidou, F., Bramer, W. M., Hsia, Y., Wong, I. C. K., Gazarian, M., Bonhoeffer, J., & Sturkenboom, M.
- Affiliations
- Erasmus MC (NL)
- University of Padua (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- St George's, University of London (GB)
- UCL School of Pharmacy (GB)
- UNSW Sydney (AU)
- University Children’s Hospital Basel (CH)
- Corresponding author
- Osokogu, Osemeke U.
- ORCID
- Venue
- Drug Safety
- Published
- 2015-02
- Volume
- 38
- Issue
- 2
- Pages
- 207-217
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- PMC
- PMC4328124
- OpenAlex
- W2022144328
- Cited by
- 31
- References
- 57
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 1
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drug Safety (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- European Commission (261060)
- ZonMw (113201007)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
- Keywords
- drug safety in children, adverse drug reactions, signal detection, spontaneous reporting systems, electronic health records, adverse event classification, ibuprofen, methylphenidate, montelukast, quinine, bullous eruption, ventricular arrhythmias, sudden death, acute kidney injury, psychosis, seizures, aplastic anemia
- MeSH terms
- Adolescent, Child, Child, Preschool, Humans, Infant, Pediatrics, Databases, Factual, Adverse Drug Reaction Reporting Systems, Data Mining, Electronic Health Records, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Fig. 1 Procedure adopted for the construction of the reference set (adapted from Coloma et al. [19]). SPC Summary of Product Characteristics, # drug–event pairs](https://figures.cochat.ai/paper-figures/922fbedefcc645eb8e35883780646737/pediatric-drug-safety-signal-detection-a-new-drugevent-reference-set-for-figure-1.jpg)